ClinicalTrials.gg
CompletedNCT04349696Updated Apr 30, 2021

Pharmacokinetic and Pharmacodynamic Study of Glufast Tablets 10mg(Mitiglinide)

A Phase 4 interventional study of Mitiglinide in Type 2 Diabetes Mellitus and Liver Dysfunction, sponsored by Orient Europharma Co., Ltd.. Completed at 2 sites in Taiwan. Open to participants aged 20 Years to 75 Years. Per ClinicalTrials.gov, last updated 2021-04-30.

Sponsored by Orient Europharma Co., Ltd. · Phase 4, Interventional, and Treatment

From the registry’s dates

  • Registered 6 years after the study started (first participant enrolled Feb 2014, registered Mar 2020).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
16
Allocation
Non-randomized
Ages
20 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 277 studies in Diabetes Mellitus, Type 2 with a site in Taiwan — 36 open to participants now, 41 under way, 14 of them phase 3. Diabetes Mellitus, Type 2 · Taiwan.

Enrollment
241st of 244
16 · median 436
Started
2014
with 11 others
Phase 4
31 of 277
2 open now
Registered
201st of 277
by date

Among the 277 studies in Diabetes Mellitus, Type 2 with a site in Taiwan, this one is the 241st largest by enrollment of the 244 interventional ones that give a count, is one of 12 that started in 2014, is one of 31 in phase 4, and was the 201st registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

36 of the 277 studies in Diabetes Mellitus, Type 2 with a site in Taiwan are open now. Recruiting first, the newest first:

31 more — sign in →

All 36 open studies →

A study can be open while its sites in Taiwan have not opened yet or have stopped. Only those recruiting at a site in Taiwan →

Who these studies take

Of the 883 Diabetes Mellitus, Type 2 studies recruiting now, 374 (42%) set no upper age limit and 383 (43%) stop at 75 or younger; 52 take children under 18; 205 take healthy volunteers.

This study: 20 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 277 studies in Diabetes Mellitus, Type 2 with a site in Taiwan, or all of them as a file.
02

Study summary

This clinical trial is designed to assess the effect of hepatic impairment on the pharmacokinetic and pharmacodynamic of glufast tablets 10 mg.

Read the detailed description

Mitiglinide calcium hydrate (Glufast Tablets) is an insulinotropic agent of the glinide class with rapid onset and is chemically designated as (+)-monocalcium bis[(2S,3a,7a-cis)-α-benzylhexahydro-γ-oxo-2-isoindolinebutyrate] dihydrate.By transiently increasing insulin secretion, mitiglinide exerts a hypoglycemic effect with rapid onset and short duration of action.This effect results from the inhibitory effect of mitiglinide on the ATP-sensitive potassium (KATP) channel current through binding to sulfonylurea receptor in pancreatic cells.

In an in vitro study, it was confirmed that mitiglinide is metabolized in liver and kidney, and the glucuronide and hydroxyl metabolites are mainly produced by drug metabolizing enzyme,UGT1A9 and 1A3, and by CYP2C9, respectively.Considering that the patient population with T2DM to be targeted appears to have hepatic impairment and the effects of liver dysfunction on pharmacokinetics and pharmacodynamics of mitiglinide are still unknown, this study was designed to investigate the pharmacokinetics (PK), pharmacodynamics (PD) and safety of mitiglinide when administered to T2DM patients with impaired hepatic function.

03

Conditions studied

  • Type 2 Diabetes Mellitus
  • Liver Dysfunction

Keywords

  • Type 2 DM
  • mitiglinide
  • Pharmacokinetics
  • Pharmacodynamics
  • liver dysfunction
04

Who can participate

Ages eligible
20 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects between 20-75 years of age, inclusive.
  • (BMI) values within 20-35 kg/m2.
  • Diagnosed as type 2 diabetes mellitus and have fasting plasma glucose (FPG) less than 200 mg/dL at screen visit (for subjects under antidiabetic treatment).
  • Having 2-hour postprandial glucose (PPG) level higher than or equal to 200 mg/dL at screen visit (for subjects who are antidiabetic treatment-naïve).
  • Having fasting plasma glucose (FPG) higher than or equal to 126 mg/dL and less than 200 mg/dL at screen visit (for subjects who are antidiabetic treatment-naïve).
  • Having been treated with dietary and exercise therapy alone or with a stable regimen for diabetes, including mitiglinide, α-glucosidase inhibitors (such as acarbose and QPS Taiwan Protocol #: OEP-P2012-01 Version: 7.0 Confidential Page 19 of 32 miglitol), metformin, sulfonylureas, DPP-IV inhibitors, thiazolidinediones (such as pioglitazone and rosiglitazone), insulin preparations or with oral antidiabetic agents in combination with insulin preparations.
  • Have signed the written to participate in the study.
  • For patients with normal hepatic function (Arm 1): characterized as normal hepatic function with laboratory tests, such as (SGOT), ALT (SGPT), -GT, alkaline phosphatase, total and albumin, within the acceptable range or results with minor deviations determined to be not by the investigator.
  • For patients with moderate impaired hepatic function (Arm 2): patients who have been diagnosed as liver cirrhosis and have system point between 7 and 9 within 3 months prior to screen visit or who have Child-Pugh system point between 7 and 9 during screening period.

Exclusion criteria

Exclusion Criteria:

  • Diagnosed as Type 1 (insulin-dependent) diabetes mellitus.
  • Having 1-hour PPG or 2-hour PPG levels > 350 mg/dL at screen visit.
  • History of diabetic ketoacidosis with or without coma.
  • With unstable or rapidly progressive diabetic proliferative retinopathy or rapidly progressive diabetic neuropathy under investigator's judgment.
  • Having renal disease or dysfunction (e.g. serum creatinine >1.6 mg/dL) and concurrent anemia.
  • Congestive heart failure (function class III to IV) or myocardial infarction within past 6 months.
  • Recent history of drug or alcohol addiction or abuse.
  • History of allergic response(s) to mitiglinide or related drugs.
  • Pregnant or lactating women or women of whom were not practicing a reliable form of .
  • Receiving any drug within one month prior to screen visit.
  • Taking high-dose sulfonylureas (e.g. taking doses exceeding 5 mg/day of glibenclamide or 80 mg/day of gliclazide or 4 mg/day of glimepiride or 5 mg/day glipizide).
  • Any clinical condition or significant concurrent disease judged by the investigator to complicate the evaluation of the study treatment.

Patients with normal hepatic function (Arm 1):

  • A positive test for surface antigen or positive antibody.
  • Presence of liver cirrhosis or liver carcinoma detected by hepatic ultrasound and deemed ineligible in the investigator's judgment.

Patients with moderate impaired hepatic function (Arm 2):

  • Having acute liver disease caused by infection or drug toxicity within one month prior to screen visit.
  • History of liver transplantation.
  • Having severe portal hypertension within one month prior to screen visit.
  • Having fluctuating or rapidly deteriorating hepatic function based on clinical signs or laboratory tests during the screening period
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
16 participants (actual)

Study arms

  • Active comparator
    T2DM with Child-Pugh A

    All subjects with T2DM with normal hepatic function received a Mitiglinide Tablets 10 mg. Intervention: Drug: Mitiglinide Tablets 10 mg

    Drug: Mitiglinide

  • Experimental
    T2DM with Child-Pugh B

    All subjects with T2DM with moderate impaired hepatic function received a MitiglinideTablets 10 mg. Intervention:Drug: Mitiglinide Tablets 10 mg

    Drug: Mitiglinide

Interventions

  • Day 1: one tablet of Mitiglinide 10mg with 240 ml of water approximately 5 mins before breakfast. An indwelling non-heparin catheter will be placed in an antecubital vein of the forearm or direct venipuncture will be adopted for blood sample collection at belowing time point: For PK evaluation: -30 (Predose), 5, 10, 15, 20, 30 min, 1.0, 1.5, 2.0, 3.0, 4.0, 5.0, 6.0, 7.0, 8.0, 9.0, 10 hr post dose (a total of 17 samples per subject) For PD evaluation: -30 (Predose), 15, 30 min, 1.0, 1.5, 2.0, 3.0, 4.0 hours post dose (a total of 8 samples per subject)

    Also known as: glufast

06

What researchers measure

Primary outcomes

  1. Peak concentration (Cmax)

    Pharmacokinetic of mitiglinide

    Time frame: 1 day

  2. Time to reach peak concentration (Tmax)

    Pharmacokinetic of mitiglinide

    Time frame: 1day

  3. Area under plasma concentration -time curve from time zero to time of last quantifiable concentration (AUC0-t)

    Pharmacokinetic of mitiglinide

    Time frame: 1 day

  4. Area under the plasma concentration-time curve from time zero to infinity of mitiglinide

    Pharmacokinetic of mitiglinide

    Time frame: 1 day

  5. The elimination rate constant

    Pharmacokinetic of mitiglinide

    Time frame: 1 day

  6. Volume of distribution (Vd/F)

    Pharmacokinetic of mitiglinide

    Time frame: 1 day

  7. Terminal elimination half-life (T1/2)

    Pharmacokinetic of mitiglinide

    Time frame: 1 day

  8. Total body clearance (CL/F)

    Pharmacokinetic of mitiglinide

    Time frame: 1 day

  9. Ratio of AUC0-t to AUC0-infinity

    Pharmacokinetic of mitiglinide

    Time frame: 1 day

  10. Area under the blood glucose concentration-time curve from time zero to time of last blood sample (AUC0-t,GLU)

    Pharmacokinetic of mitiglinide

    Time frame: 1 day

  11. Area under the blood glucose concentration(change from baseline)-time curve from time zero to time of last blood sample (ΔAUC0-t,GLU)

    Pharmacokinetic of mitiglinide

    Time frame: 1 day

  12. Blood glucose concentration change from baseline at 2 hours after drug administration

    Pharmacokinetic of mitiglinide

    Time frame: 1 day

07

Study locations

2 sites
  • Chiayi Chang Gung Memorial Hospital
    Chiayi City, 61363, Taiwan
  • Taipei Veterans General Hospital
    Taipei, 11217, Taiwan
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2014 to primary completion in Apr 2018, 50 months.

Of 132 industry-sponsored phase 4 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 28. This study's 50 months is above that.

Counting every sponsor, half of 452 studies reached it within 24 months; a quarter within 13 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 3, 2020
First posted
Apr 16, 2020
StartActual
Feb 11, 2014
Primary completionActual
Apr 2018
CompletionActual
Apr 2018
Last update
Apr 30, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 30, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04349696
Lead sponsor
Orient Europharma Co., Ltd.
Responsible party
Sponsor
First posted
Apr 16, 2020
Start date
Feb 11, 2014
Primary completion
Apr 2018
Completion
Apr 2018
Last update
Apr 30, 2021

Study contacts

Yi-Hsiang Huang, Ph.D
principal investigator · Taipei Veterans General Hospital, Taiwan
Wei-Ming Chen, MD
principal investigator · Chang Gung Memorial Hospital

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Mitiglinide

Start the discussion